Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VXCO-100 in Healthy Adults
NCT05870839Phase 1Completed
- Sponsor
- Vaccine Industrial Company
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of VXCO-100 in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Vaccine Industrial Company. Primary endpoints: Solicited local adverse events at 7 days, Solicited systemic adverse events at 7 days and 2 more. Started May 2023; status: completed.
02
Drugs
VXCO-100
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05870839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05870839.